Experts Share Top Highlights from the 2024 SGO Annual Meeting on Women’s Cancer

Leslie M. Randall, MD, MAS

In case you missed the key sessions at the 2024 SGO Annual Meeting on Women's Cancer or want to know more about updates from across the field, gynecologic oncology experts shared their most notable takeaways from the conference during interviews with OncLive^®.

Dimitrios Nasioudis, MD, Perelman School of Medicine at the University of Pennsylvania

“Key presentations, [including] the overall survival [OS] data from immunotherapy trials in the first line, were exciting to see and confirmed that the addition of immunotherapy in the first line for endometrial cancer is effective. There were also exciting data regarding novel antibody-drug conjugates [ADCs], and that [creates a path] for new treatment options for patients.”

Chrstian Marth, MD, PhD, Innsbruck Medical University

“The 2024 SGO Annual Meeting was great. I saw interesting presentations, especially in the endometrial cancer first-line setting with pembrolizumab (Keytruda) and dostarlimab-gxly (Jemperli). [Investigators presented updated findings from the phase 3] NRG-GY018 (NCT03914612) and RUBY (NCT03981796) trials, [where] we saw OS benefits [with pembrolizumab plus chemotherapy and dostarlimab plus chemotherapy, respectively], which is good news for our patients [with endometrial cancer]. Combination [regimens] with PARP inhibitors might also have, at least in a subset of patients, a benefit. This is a good future.”

Tiffany Sia, MD, Memorial Sloan Kettering Cancer Center

“I’ve been excited to see a lot of the data on disaggregating large database data on race and ethnicity.”

Ying Liu, MD, MPH, Memorial Sloan Kettering Cancer Center

“It's always a challenge to get data [about health equity and health disparities] and describe them, so it’s exciting that the field is paying attention to that and talking about ways to measure it. There was a whole session dedicated to menopause and managing the symptoms of risk-reducing surgery or early treatment-induced menopause. It acknowledges the flip side; we talk a lot about treatments and how they help patients live longer, but this [research was] focused on making sure they live long, live well, and treat these adverse effects.”

Leslie M. Randall, MD, MAS, School of Medicine Obstetrics and Gynecology at Virginia Commonwealth University

“[I enjoyed] the late-breaking abstract sessions. We saw great data with all the new therapeutics coming about. We have surgical trials, [because some] gynecologic oncologists are also surgeons. [These include trials investigating] robotic surgery, local cancer, and hyperthermic intraperitoneal chemotherapy for ovarian cancer. Those were not presented at this meeting, but to see the energy behind surgical trials shown at this meeting was exciting, and I’m looking forward to those results to come in the future.”

Judy Hayek, MD, State University of New York Downstate College of Medicine

“It’s an exciting time; there’s a lot coming out. My favorite sessions were the late-breaking sessions, where the big studies or sub-analyses were announced. It helps us practitioners have guidance when we’re caring for our patients.”

Bradley R. Corr, MD, University of Colorado Anschutz Medical Campus

“I’m always excited to see information about PARP inhibitors in endometrial cancer. There were a lot of great data and improvement with the RUBY part 2 trial, the [phase 3] DUO-E trial [NCT04269200], and our data [with rucaparib (Rubraca) maintenance therapy in patients with metastatic or recurrent endometrial cancer]. Seeing all the improvements presented with the use of immunotherapy in endometrial cancer [was important] as well.”

Oliver Dorigo, MD, PhD, Stanford Cancer Institute

“I’ve always been excited about immunotherapy. I’ve been in this field for many years, and it is fascinating and satisfying to see how immunotherapy has now added so much benefit to many of our patients, particularly those with cervical cancer and endometrial cancer. We have seen tremendous benefits for patients with metastatic cervical cancer. We know adding immunotherapy to patients with locoregional, advanced cervical cancer [generates] survival benefits. It’s an opportunity for us to do more with immunotherapy to stimulate antitumor responses for better long-duration outcomes. I’m also encouraged by the new research, particularly in liquid biopsies, that might in the future replace the common tumor markers we’re using at this point. We are early in this development, but I’ve seen encouraging data at this meeting that point to the potential value of these types of liquid biopsies. There is a lot of work still to be done, but I’m excited to see that SGO and its members have embraced these new technologies and are starting to investigate those.”

Mansoor Raza Mirza, MD, Copenhagen University Hospital

“Some of the major news from SGO were the results from RUBY part 2. The other interesting data were the data on DS-6000, an ADC. The early results will [help this agent] move to a randomized trial. We also saw interesting results of another ADC, fam-trastuzumab deruxtecan-nxki (Enhertu). All these new drugs are coming in ovarian cancer and endometrial cancer that will move the needle to the next level. We heard that there is OS benefit with CRX100 [in patients with ovarian cancer], which is extremely comforting because we have not seen an OS benefit in this population for a long time. This SGO Annual Meeting has given us great news to take back home to our patients.”

Check out all of OncLive’s coverage from the 2024 SGO Annual Meeting on Women’s Cancer here.